European Commission logo
English English
CORDIS - EU research results

Innovations to accelerate vaccine development and manufacture

Project description

Driving forward vaccine development

Vaccines protect millions from death, illness and disability. The COVID-19 pandemic has highlighted many challenges hampering vaccine development. The EU funded Inno4Vac project will address scientific bottlenecks in vaccine development. Inno4Vac proposes to develop predictive biological and mathematical models of vaccine performance and manufacturing. Artificial intelligence combined with big data and computational modelling will be used to build an open-access and cloud-based platform for in silico vaccine efficacy assessment and development. Controlled human infection models and cell-based human in vitro 3D models will be developed to enable early evaluation of vaccine efficacy and prediction of immune protection. Finally, an open source in silico simulation platform will guide the production of vaccine candidates and associated stability testing.


Inno4Vac proposes an ambitious programme that will harness the latest advances in immunology, disease modelling, and modelling for tackling persistent scientific bottlenecks in vaccine development and for de-risking and accelerating this process. To reach this aim the project is divided into four interlinked subtopics. In Subtopic 1, artificial intelligence in combination with big data analysis and computational modelling will be used to build an open-access and cloud-based platform for in silico vaccine efficacy assessment and development. Subtopic 2 will develop new and improved controlled human infection models (CHIM) against influenza, RSV and C. difficile that will enable early vaccine efficacy evaluation. Subtopic 3 will contribute to the development of cell-based human in vitro 3D models that resemble the in vivo situation of an infection at the mucosa and more reliably predict immune protection. These models will be combined with the development of related functional immune assays for clinically relevant (surrogate) endpoints. Finally, Subtopic 4 will develop a modular one-stop computational platform for in silico modelling of vaccine bio-manufacturing and stability testing.
In parallel to the scientific-technical work, the partners will develop strategies and roadmaps for positioning the newly developed models in the regulatory framework and integrating them into pharmaceutical vaccine development. The overall workplan is underpinned by horizontal activities on coordination/management and dissemination/communication, including data management and future sustainability.
To achieve these ambitious objectives, Inno4Vacc has assembled a multidisciplinary consortium from academic and research institutions, industries, regulatory bodies, and vaccine R&D alliances. This unique partnership brings together clinical, immunological, microbiological, systems biology, mathematical models, and regulatory expertise and includes world-leaders in each respective field.


Net EU contribution
€ 1 698 967,50
69115 Heidelberg

See on map

Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Activity type
Research Organisations
Total cost
€ 3 984 601,50

Participants (40)